Back to search

Peptide record

TPDB27165

Antibacterial Anticancer Toxicity modified_plain modified
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB27165
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia
modified_plain
Yes
A 9-aa modified multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Modified, details unspecified
Sequence
XXWXXXWWX
Physicochemical Analysis
C33H32N6O4
ARNDCEQGHILKMFPSTYV
W
576.65
6.02
0
0
3
-0
-5.55
-0.300
0.00
Mammalian: Yeast: E.coli:
16500
2861.33
0
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
0
L
0
K
0
M
0
F
0
P
0
S
0
T
3
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 3 Y: 0 V: 0
Chemical Descriptors
9
C33H32N6O4
576.65
6.02
-0
-5.55
-0.300
Evidence Records 6 records
Evidence 1 Activity

Activity

IC50
Toxicity
323±33 µM
Cytotoxic
IC50 | 323±33 | µM | target cell: Human fibroblasts MRC-5

Target

Human fibroblasts MRC-5

Source & Reference

NA
DBAASP
Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. | J Med Chem | 2016
Evidence 2 Activity

Activity

IC50
Toxicity
97.7±5.1 µM
Cytotoxic
IC50 | 97.7±5.1 | µM | target cell: Human fibroblasts MRC-5

Target

Human fibroblasts MRC-5

Source & Reference

NA
DBAASP
Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. | J Med Chem | 2016
Evidence 3 Activity

Activity

IC50
Toxicity
516±5.2 µM
Cytotoxic
IC50 | 516±5.2 | µM | target cell: Human fibroblasts MRC-5

Target

Human fibroblasts MRC-5

Source & Reference

NA
DBAASP
Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. | J Med Chem | 2016
Evidence 4 Activity

Activity

IC50
Toxicity
695 µM
Hemolytic Cytotoxic
Hemolytic_activity: Human red blood cells (RBC): IC50>695 µM | Cytotoxicity: HUVEC: IC50> 347 µM MRC-5: IC50=323 ± 33 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
BMC Cancer. 2011 Mar 31 11:116.
Evidence 5 Activity

Activity

IC50
Toxicity
97.7
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: MRC-5: IC50=97.7 ± 5.1 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
J Med Chem. 2016 Apr 14 59(7):2918-27.
Evidence 6 Activity

Activity

IC50
Toxicity
516
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: MRC-5: IC50=516 ± 5.2 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
J Med Chem. 2016 Apr 14 59(7):2918-27.